The Golden Era of Genomics and Management of Acute Myeloid Leukemia
April 12, 2012
Cancer treatment is undergoing significant developments and entering the new golden era of genomics which has true potentials for the promise of personalized medicine. Large-scale sequencing is changing our understanding of malignant disorders particularly acute myeloid leukemia.
It Is Better to Do RIC Without ATG
October 24, 2011
There has been an ongoing debate about the role of ATG in reduced intensity conditioning (RIC) HSCT, and there are still bone marrow transplant centers that use ATG in the RIC setting, and their main argument is that ATG could help with engraftment and reducing the risk of GVHD.
Adoptive T-Cell Immunotherapy: One Step Forward
September 14, 2011
A recent case report in the New England Journal of Medicine highlights the promising potentials of adoptive T-cell immunotherapy by redirecting them, through chimeric antigen receptors, as a novel and effective therapeutic modality for cancer.
Equine ATG as the First-Line Treatment for Aplastic Anemia
August 24, 2011
Equine ATG has been used for the treatment of severe aplastic anemia since the 1980s. Rabbit ATG is used in many parts of the world including South America, Japan, and European countries. The results of a randomized study of equine versus rabbit ATG showed that rabbit ATG was inferior to equine ATG.
Is There a Virus-Versus-Leukemia Effect?
June 21, 2011
The current dogma considers CMV seropositivity being associated with inferior outcomes HSCT. However, there has been a notion of “virus-versus-leukemia” effect since the 1980s.